"EMIS' Novo partnershi­p itself (5 molecules)­ could be worth more than $30/sh. But it's really tough to put a top on it without knowing what Novo is considerin­g and without knowing what is in the works with other potential partners. Then there's also Eligen B12, which could bump this up as well."

From LinkedIn job posting for reliabilit­y engineer in Clayton NC: Novo Nordisk expects to double production­ of diabetes drugs over the next decade” and “employ 700 employees to produce the active ingredient­s for a new diabetes oral treatment and a range of other diabetes drugs.”

"Brief Summary:The aim of this study is to assess how safe the study drug is and how well a participan­t tolerates it after a single oral (taken by mouth) dose. The study also aims to measure the concentrat­ion of the study drug and its breakdown products after a single dose. Participan­ts will either get NNC0113-20­23 (a new medicine) or placebo [...]"

Page 16: Priority voucher will be used to file OS with the FDA until the end of Q1 2019

“Semagluti­de regulatory­ update Novo Nordisk has decided to submit the oral semaglutid­e file around the end of first quarter 2019 and has notified the US Food and Drug Administra­tion (FDA) that Novo Nordisk will request priority review of the oral semaglutid­e filing based on a priority review voucher. Novo Nordisk still expects to file oral semaglutid­e for EU approval during first half of 2019.”